Stem cells in the bone marrow keep replenishing us with blood cells until the day we die. They do this by dividing into a daughter cell that becomes a blood cell, and a second cell that remains a stem cell. But every time a cell divides, mistakes can occur that change the cell’s genome and increase the risk of it becoming a cancer cell.
A team of researchers from the Berlin Institute of Health at Charité, the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), the German Cancer Research Center (DKFZ), and Harvard Medical School has now discovered an elegant mechanism that protects stem cells from this risk.
Our blood contains many different types of cells that are involved in our immune system, in transporting oxygen, and in healing wounds. Simon Haas of the BIH, the MDC, and HI-STEM explains that our bodies dispose of old cells and form about a billion new ones every day: “It might even be more than that, depending on what the individual needs. A COVID patient, for instance, will need more immune cells to help them fight off the infection. And all those new cells come from so called blood stem cells in our bone marrow. They keep doing their job for our entire lives.”
Passive and active protection for stem cells
© BIH/ S. Haas
But because these stem cells have to produce so many cells, their genome needs extremely good protection against damage. “Any errors will be passed on to the daughter cells and multiplied,” says Haas. Researchers have therefore long been trying to track down the mechanism that ensures stem cells only rarely mutate. One of them came to light a while ago: “Within the bone marrow, the stem cells reside in a stem cell niche that protects them from harmful environmental factors,” says Andreas Trumpp, director of HI-STEM and head of the Stem Cells and Cancer Division at DKFZ in Heidelberg. “They are usually maintained in a dormant state and only wake up once they are needed. It’s a very reliable system. The protection only starts to decline in old age, which is why leukemia sadly occurs more frequently in older people.“
But this passive protection is clearly just one part of the secret of our unscathed stem cells. Haas and his team have now discovered that stem cells do occasionally mutate, but it appears that the body recognizes and eliminates them before they can do any damage. “The stem cell niche contains immune cells called T cells, and they regularly check which proteins are being presented on the surface of the stem cells,” says Haas. “If the immune cells detect cancerous changes in a stem cell, they activate it and drive it out of the niche.”
Single-cell technologies show that stem cells communicate with T cells
The researchers discovered this interaction between the T cells and the stem cells rather by chance. Pablo Hernández-Malmierca, the lead author of the study, was investigating the stem cells using gene expression analyses and single-cell technologies. “That’s how we learned that the stem cells in bone marrow produce all the proteins needed for communicating with T cells in the bone marrow niche.”
The team was most surprised to find that the stem cells appear to use signaling molecules that only a few specialized cell types deploy for communicating with T cells. “The only cells that communicate via MHC class II molecules on their surface are professional antigen-presenting cells,” says Haas. “At first we couldn’t believe that stem cells in bone marrow were also using this specific pathway.” To check whether the stem cells actually used the MHC II molecules they were producing, second lead author Dominik Vonficht brought stem cells and T cells together in a petri dish.
“We discovered that the mutated stem cells activate the T cells by presenting fragments of their mutated proteins on the MHC II molecules. We also saw that the T cells activate the stem cells by using their T cell receptor to bind to the MHC II molecules. So the communication works in both directions,” says Hernández-Malmierca. “The activated stem cells do divide, but this time both daughter cells differentiate to form blood cells – instead of one remaining a stem cell. This removes the danger of a mutated stem cell continuing to produce mutated offspring.”
Rewriting the textbooks
The researchers also showed that the stem-cell safety mechanism functions via the MHC II pathway in mice. “We bred mice with two different types of stem cells: Half the stem cells were healthy, and the other half presented fragments of an abnormal protein on their surface via the MHC II molecule. When we gave the mice T cells whose receptors recognized the abnormal protein, the affected stem cells rapidly disappeared from the bone marrow, leaving only the healthy stem cells behind. This protected the mice from developing leukemia,” explains Alexandra Schnell of Harvard Medical School. Analysis of clinical data showed that the newly discovered mechanism also removes abnormal stem cells to prevent the accumulation of mutations in humans.
Haas – whose research group is part of the joint focus area “Single Cell Approaches for Personalized Medicine” at the BIH, Charité, and the MDC – is delighted that the new technologies are rewriting the textbooks. “It used to be taken as given that only dendritic cells, macrophages, and B cells have MHC II molecules and present antigens via this route. We’re very surprised to have discovered that blood stem cells in bone marrow also use this very same mechanism to communicate with T cells – and I suspect that will also be the case for most of our colleagues.”
About the Berlin Institute of Health at Charité (BIH)
The mission of the Berlin Institute of Health at Charité (BIH) is medical translation: transferring biomedical research findings into novel approaches to personalized prediction, prevention, diagnostics and therapies and, conversely, using clinical observations to develop new research ideas. The aim is to deliver relevant medical benefits to patients and the population at large. As the translational research unit within Charité, the BIH is also committed to establishing a comprehensive translational ecosystem – one that places emphasis on a system-wide understanding of health and disease and that promotes change in the biomedical translational research culture. The BIH was founded in 2013 and is funded 90 percent by the Federal Ministry of Education and Research (BMBF) and 10 percent by the State of Berlin. The founding institutions, Charité – Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), were independent member entities within the BIH until 2020. Since 2021 the BIH has been integrated into Charité as its so-called third pillar. The MDC is now the Privileged Partner of the BIH.
Dr. Stefanie Seltmann
Head of Communications
Berlin Institute of Health at Charité (BIH)
+49 (0)30 450 543019
Merkmale dieser Pressemitteilung:
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).